- Home
- UTHR vs NIO Comparison
UTHR vs NIO Comparison
Compare UTHR & NIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTHR
- NIO
- Stock Information
- Founded
- UTHR 1996
- NIO 2014
- Country
- UTHR United States
- NIO China
- Employees
- UTHR N/A
- NIO N/A
- Industry
- UTHR Biotechnology: Pharmaceutical Preparations
- NIO Auto Manufacturing
- Sector
- UTHR Health Care
- NIO Consumer Discretionary
- Exchange
- UTHR Nasdaq
- NIO Nasdaq
- Market Cap
- UTHR 20.7B
- NIO 16.5B
- IPO Year
- UTHR 1999
- NIO 2018
- Fundamental
- Price
- UTHR $437.62
- NIO $7.41
- Analyst Decision
- UTHR Buy
- NIO Buy
- Analyst Count
- UTHR 16
- NIO 9
- Target Price
- UTHR $472.94
- NIO $6.63
- AVG Volume (30 Days)
- UTHR 629.5K
- NIO 58.8M
- Earning Date
- UTHR 10-29-2025
- NIO 11-19-2025
- Dividend Yield
- UTHR N/A
- NIO N/A
- EPS Growth
- UTHR 16.08
- NIO N/A
- EPS
- UTHR 26.38
- NIO N/A
- Revenue
- UTHR $3,128,400,000.00
- NIO $9,690,436,500.00
- Revenue This Year
- UTHR $13.82
- NIO $37.34
- Revenue Next Year
- UTHR $5.71
- NIO $45.10
- P/E Ratio
- UTHR $16.63
- NIO N/A
- Revenue Growth
- UTHR 13.50
- NIO 9.28
- 52 Week Low
- UTHR $266.98
- NIO $3.02
- 52 Week High
- UTHR $479.50
- NIO $8.02
- Technical
- Relative Strength Index (RSI)
- UTHR 54.98
- NIO 58.38
- Support Level
- UTHR $409.15
- NIO $6.85
- Resistance Level
- UTHR $479.50
- NIO $7.33
- Average True Range (ATR)
- UTHR 13.84
- NIO 0.29
- MACD
- UTHR -0.64
- NIO 0.01
- Stochastic Oscillator
- UTHR 40.46
- NIO 91.46
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
About NIO NIO Inc. American depositary shares each representing one ordinary share
Nio is a leading electric vehicle maker, targeting the premium segment. Founded in November 2014, Nio designs, develops, jointly manufactures, and sells premium smart electric vehicles. The company differentiates itself through continuous technological breakthroughs and innovations such as battery swapping and autonomous driving technologies. Nio launched its first model, its ES8 seven-seater electric SUV, in December 2017, and began deliveries in June 2018. Its current model portfolio includes midsize to large sedans and SUVs. It sold around 222,000 EVs in 2024, accounting for about 2% of the China passenger new energy vehicle market.